CytomX Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Financial statements are unaudited. CytomX is a clinical-stage oncology company developing conditionally activated biologics using its Probody platform; it has no approved products and no product-sales revenue.
Financial results and position
Amounts in millions, except per-share data. Comparisons are with the corresponding 2021 periods.
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $16.9 | $17.6 | $52.2 | $49.8 |
| Research and development | $30.4 | $29.1 | $92.1 | $77.6 |
| General and administrative | $10.5 | $11.1 | $32.8 | $29.7 |
| Operating loss | $23.9 | $22.6 | $72.7 | $57.5 |
| Net loss | $23.3 | $22.6 | $71.4 | $57.4 |
| Basic and diluted loss per share | $0.35 | $0.35 | $1.09 | $0.90 |
| Operating cash used | — | — | $109.4 | $87.8 |
Revenue came from collaboration agreements, not product sales. Q3 revenue declined $0.7 million year over year; nine-month revenue increased $2.4 million. For the nine months, higher AbbVie revenue was partly offset by lower Amgen revenue, which the company attributed to estimated project completion progress. Gross margin is not presented as a clear standalone metric in the filing.
At September 30, cash and cash equivalents were $95.0 million and short-term investments were $99.3 million, totaling $194.3 million, versus $305.2 million at December 31, 2021. Cash, cash equivalents and restricted cash declined $110.5 million during the first nine months. Stockholders’ equity was $28.5 million, down from $89.4 million at year-end 2021; accumulated deficit was $605.1 million. The filing reports no borrowings or debt balance. Total liabilities were $198.0 million, including $146.4 million of deferred revenue and operating lease liabilities.
Management estimated existing capital resources would fund operations into 2025 under its current operating plan, while noting that additional funding will be needed in the future and that spending or financing assumptions may change. Collaboration cash received in prior periods is recognized as revenue over performance periods; deferred revenue fell from $194.9 million at year-end 2021 to $146.4 million at September 30, 2022.
Material changes and operating developments
- Nine-month net loss increased $14.0 million year over year, and operating cash use increased $21.6 million. R&D expense rose $14.5 million, reflecting restructuring charges and higher lab contract and personnel costs; G&A increased $3.1 million.
- On July 13, 2022, CytomX announced a workforce reduction of approximately 40% to prioritize its emerging preclinical and early clinical pipeline and collaborations. It recorded approximately $7.1 million of restructuring charges through September 30 and estimated total costs of $7.9 million, with another $0.8 million expected in Q4 2022. Completion was expected by year-end 2022.
- For praluzatamab ravtansine (CX-2009), July Phase 2 topline results showed Arm A met its confirmed objective response-rate endpoint of greater than 10%. The filing reported adverse-event discontinuation in 30% of Arm A patients and Grade 3 or higher ocular and neuropathic toxicities of 15% and 10%, respectively. Arm B did not pass its futility boundary; enrollment in Arms B and C was discontinued. CytomX said it would seek a partner to develop the program further.
- CX-2029 enrollment was complete in the sqNSCLC, HNSCC and E/GEJ cohorts; the DLBCL cohort was deprioritized and enrolled no patients. A sqNSCLC data update was expected in Q4 2022, while E/GEJ data continued to mature.
- Partnered CX-904, an EGFR/CD3 T-cell engager, began a Phase 1 study in May 2022; dose escalation enrollment was ongoing. IND submissions for wholly owned CX-801 and CX-2051 were planned for the second half of 2023.
Outlook, risks and contingencies
- The company expects significant losses to continue and does not expect near-term product-sales revenue. Future collaboration revenue depends on partner activity, research progress, milestones and other contractual terms; potential milestone payments are generally excluded from transaction prices while constrained.
- Key risks include clinical-trial safety and efficacy uncertainty, enrollment or regulatory delays, reliance on collaborators and third-party manufacturers, limited access to additional capital, and uncertainty about savings from restructuring. COVID-19 could continue to affect research, trials, manufacturing and operations.
- The Vytacera Bio patent-infringement suit seeks unspecified damages. CytomX filed a motion to dismiss in September 2022; case deadlines were stayed pending resolution. The company says it will defend the case and recorded no liability.
- California was examining CytomX’s 2017 and 2018 revenue-apportionment tax positions. The state had proposed no adjustments as of filing; the company could not estimate timing or potential impact, but did not anticipate a material effect.
- The filing lists a Bristol Myers Squibb collaboration amendment effective October 11, 2022, after quarter-end; certain exhibit information is confidentially omitted, so its terms are not clear from the filing text provided.
Important facts for investors to verify
- Whether the projected cash runway into 2025 remains supported by current spending, collaboration receipts and restructuring savings—and what financing may be required.
- Final CX-2029 cohort data and the safety, efficacy and dose-escalation findings for CX-904; also the outcomes and timing of planned CX-801 and CX-2051 IND submissions.
- Whether CytomX secures a partner for praluzatamab ravtansine and whether the discontinued breast-cancer arms or emerging safety findings affect its development prospects.
- Progress and revenue recognition under collaboration agreements, including partner decisions, deferred-revenue releases, milestone constraints and the terms of the BMS amendment effective after quarter-end.
- Resolution and potential financial consequences of the Vytacera litigation and California tax examination.